Sarah Aiosa – SVP & President Latin America, MSD
Sarah Aiosa, SVP and President of MSD (known as Merck & Co. in the U.S. and Canada) for Latin America, highlights nearly four years of strong growth built on a…
Landsteiner Scientific is a Mexican pharmaceutical company founded in 1998 dedicated to research, development, manufacturing, distribution and marketing of health products. The company employs 1,000 people and covers domestic as well as international markets through several business lines, encompassing prescription drugs, generics, biotech products, high specialty and in-store brands. The product portfolio contains over 70 products in 300 different presentations divided among 17 therapeutic areas. In 2013 the company entered the field of genomic medicine with the acquisition of Neopharm Obesity, a company based in Seville, Spain.
Contact details
Landsteiner Scientific
Av. Periférico Sur no. 4118, Piso 6
Col. Jardines de Pedregal
CP 01900, México DF
MEXICO
Tel: +52 (55) 5449 3690
Website: www.landsteiner.com
Sarah Aiosa, SVP and President of MSD (known as Merck & Co. in the U.S. and Canada) for Latin America, highlights nearly four years of strong growth built on a…
Pharmaceutical innovators are sounding the alarm on Mexico’s healthcare reforms, despite the government’s bold claims. At industry group AMIIF’s 75th anniversary, Health Secretary David Kershenobich hailed the Sheinbaum administration’s investments…
In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract…
Mexico has a long history of public healthcare reforms that have fluctuated along with the changing tides of the country’s government. The latest is an ambitious plan for the Institute…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example,…
Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential…
Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in…
Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent…
In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms…
Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an…
This interview explores Esmeralda Ortiz’s transformative leadership at Grupo Loeffler Russek (GLR), where she has worked to professionalize operations, strengthen the product portfolio, and position the company for sustainable growth.…
Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical…
See our Cookie Privacy Policy Here
